Evidence map›Paper›PMID 27130143›Full record

Trial reportAnnals of neurology2016

Recombinant human erythropoietin improves neurological outcomes in very preterm infants.

Juan Song, Huiqing Sun, Falin Xu, Wenqing Kang, Liang Gao, Jiajia Guo, Yanhua Zhang, Lei Xia, Xiaoyang Wang, Changlian Zhu

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03110341 (Effect of Early Application of Recombinant Human Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome), which is not on this map. Cited by 60 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 10 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03110341 phase3unknown statusnot on this mapstarted 2017, after this paper: background citation

Effect of Early Application of Recombinant Human Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome

TypeinterventionalSponsorFirst Affiliated Hospital Xi'an Jiaotong UniversityRan2017 to 2019Enrolled400ConditionsPremature Infants, Intracranial Hemorrhages, Periventricular Leukomalacia, Cerebral PalsyArmsErythropoietin, Normal saline
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 10 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Perinatal Neuroprotection in Preterm Birth.Geburtshilfe und Frauenheilkunde · 2025
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Juan SongDepartment of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Huiqing SunDepartment of Pediatrics, Zhengzhou Children's Hospital, Zhengzhou, China.
Falin XuDepartment of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wenqing KangDepartment of Pediatrics, Zhengzhou Children's Hospital, Zhengzhou, China.
Liang GaoDepartment of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiajia GuoDepartment of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yanhua ZhangDepartment of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lei XiaDepartment of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaoyang WangDepartment of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Changlian ZhuDepartment of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Third Affiliated Hospital of Zhengzhou University · CNZhengzhou Children's Hospital · CNUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and safety of repeated low-dose human recombinant erythropoietin (rhEPO) in the improvement of neurological outcomes in very preterm infants.

methodsA total of 800 infants of ≤32-week gestational age who had been in an intensive care unit within 72 hours after birth were included in the trial between January 2009 and June 2013. Preterm infants were randomly assigned to receive rhEPO (500IU/kg; n = 366) or placebo (n = 377) intravenously within 72 hours after birth and then once every other day for 2 weeks. The primary outcome was death or moderate to severe neurological disability assessed at 18 months of corrected age.

resultsDeath and moderate/severe neurological disability occurred in 91 of 338 very preterm infants (26.9%) in the placebo group and in 43 of 330 very preterm infants (13.0%) in the rhEPO treatment group (relative risk [RR] = 0.40, 95% confidence interval [CI] = 0.27-0.59, p < 0.001) at 18 months of corrected age. The rate of moderate/severe neurological disability in the rhEPO group (22 of 309, 7.1%) was significantly lower compared to the placebo group (57 of 304, 18.8%; RR = 0.32, 95% CI = 0.19-0.55, p < 0.001), and no excess adverse events were observed.

interpretationRepeated low-dose rhEPO treatment reduced the risk of long-term neurological disability in very preterm infants with no obvious adverse effects. Ann Neurol 2016;80:24-34.

Indexed as

Birth WeightDisability EvaluationErythropoietinFemaleGestational AgeHumansInfant, Extremely PrematureInfant, NewbornInfant, PrematureMaleMortalityRecombinant ProteinsErythropoietinRecombinant Proteins

Identifiers

PMID27130143
PMCPMC5084793
OpenAlexW2342987015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.